Pathology and Laboratory Medicine, Davis Memorial Hospital, Elkins, WV 26241, USA.
Ann Diagn Pathol. 2011 Dec;15(6):407-13. doi: 10.1016/j.anndiagpath.2011.05.007. Epub 2011 Oct 7.
We present 19 cases of primary breast malignant fibrous histiocytoma (MFH) or myxofibrosarcoma/pleomorphic sarcoma not otherwise specified, the largest series to date, and compare our results with those in the literature to better define MFH in this anatomical location. Twenty-seven cases (MFH, myxofibrosarcoma, or pleomorphic sarcoma not otherwise specified) were reviewed using World Health Organization and French Federation of Cancer Centers criteria. Inclusion required location within breast parenchyma without extensive chest wall involvement. Morphological features were recorded, and immunohistochemistry was applied. Clinical data were extracted from patients' medical records. Clinically, there was 1 male patient. Of 15 patients with follow-up, 5 (33% overall) died of disease within an average of 7 months after diagnosis. Distant metastases and older patient age were associated with poor survival. Storiform-pleomorphic subtype was most common (10/19) with myxofibrosarcoma (6/19) and giant cell subtype (1/19) also observed. Unique lymphocyte-rich (1/19) and pleomorphic hyalinizing angiectatic tumor-like (1/19) morphologies are presented. Immunohistochemistry demonstrated expression of CD68 (71%), focal smooth muscle actin (36%), with rare focal estrogen and progesterone receptor immunoreactivity. All cases were negative for CD34, S-100 protein, desmin 33, and keratins, including CK7, CK20, CK5/6, and CK18. Malignant fibrous histiocytoma occurs as a primary lesion in breast parenchyma. Attention to morphological detail and immunohistochemistry avoids misdiagnosis. Entrapped breast ductal epithelium should not be misinterpreted as the epithelial component of a biphasic tumor. A florid lymphoid response should not be confused with metaplastic carcinoma. Pleomorphic hyalinizing angiectatic tumor-like features may be observed in MFH. Our study confirms the presence of MFH in breast and presents unique morphological observations of primary breast MFH.
我们报告了 19 例原发性乳腺恶性纤维组织细胞瘤(MFH)或黏液纤维肉瘤/多形性肉瘤,这是迄今为止最大的系列,我们将结果与文献中的结果进行比较,以更好地定义该解剖部位的 MFH。使用世界卫生组织和法国癌症中心联合会标准回顾了 27 例病例(MFH、黏液纤维肉瘤或多形性肉瘤)。纳入标准为位于乳腺实质内,无广泛胸壁受累。记录形态学特征,并应用免疫组织化学。从患者的病历中提取临床数据。临床上,有 1 例男性患者。15 例有随访的患者中,5 例(总体 33%)在诊断后平均 7 个月内死于疾病。远处转移和老年患者年龄与不良生存相关。梭形-多形性亚型最常见(19 例中有 10 例),也观察到黏液纤维肉瘤(19 例中有 6 例)和巨细胞亚型(19 例中有 1 例)。呈现独特的淋巴细胞丰富型(19 例中有 1 例)和多形性玻璃样血管扩张性肿瘤样(19 例中有 1 例)形态。免疫组织化学显示 CD68 表达(71%),局灶性平滑肌肌动蛋白(36%),罕见局灶性雌激素和孕激素受体免疫反应性。所有病例均为 CD34、S-100 蛋白、结蛋白 33 和角蛋白阴性,包括 CK7、CK20、CK5/6 和 CK18。恶性纤维组织细胞瘤作为乳腺实质的原发性病变发生。注意形态学细节和免疫组织化学可避免误诊。不应将包裹的乳腺导管上皮错误地解释为双相肿瘤的上皮成分。丰富的淋巴样反应不应与化生癌混淆。多形性玻璃样血管扩张性肿瘤样特征可能在 MFH 中观察到。我们的研究证实了 MFH 在乳腺中的存在,并提出了原发性乳腺 MFH 的独特形态学观察结果。